Uniting innate and adaptive immunity in glioblastoma; an α-CTLA-4 quest

Abstract

Immunotherapies have thus far led to disappointing outcomes in patients suffering from glioblastoma. Published in Immunity, Chen et al.'s recent study shows the therapeutic potential of an αCTLA-4 antibody (Ab), specifically in murine mesenchymal-like glioblastoma. αCTLA-4 Ab efficacy relied on the distinctive cooperation between CD4⁺ Th1 T cells and microglia, unleashing a potent antitumor response.